Swedish Orphan Biovitrum (SOBI) Stock Overview
A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SOBI Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 446.60 |
| 52 Week High | SEK 451.80 |
| 52 Week Low | SEK 261.20 |
| Beta | 0.27 |
| 1 Month Change | 1.27% |
| 3 Month Change | 18.59% |
| 1 Year Change | 45.38% |
| 3 Year Change | 101.72% |
| 5 Year Change | 185.55% |
| Change since IPO | 300.54% |
Recent News & Updates
Recent updates
Analysis Article • May 06
We Think You Can Look Beyond Swedish Orphan Biovitrum's (STO:SOBI) Lackluster Earnings
The market was pleased with the recent earnings report from Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ), despite...Analysis Article • May 01
Results: Swedish Orphan Biovitrum AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Investors in Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ) had a good week, as its shares rose 6.8% to close at kr428...
Narrative Update • Apr 21
SOBI: Kidney And Sepsis Advances Will Steadily Shape A More Balanced Outlook
Analysts have nudged the fair value estimate higher to SEK 433.18 from SEK 428.50, reflecting recent SEK 470 to SEK 500 price target increases and a shift toward a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Swedish Orphan Biovitrum presents a mixed picture, with some analysts lifting price targets and others turning more cautious on the shares.Narrative Update • Apr 07
SOBI: Kidney And Sepsis Pipeline Progress Will Shape A More Balanced Outlook
The analyst price target for Swedish Orphan Biovitrum has been raised by SEK 4.90 to SEK 428.50, as analysts reference recent target increases from SEK 395 to SEK 470 and from SEK 470 to SEK 500, alongside updated assumptions for revenue growth, profit margins and future P/E. Analyst Commentary Recent research opinions on Swedish Orphan Biovitrum present a mixed picture, with several price target adjustments and rating changes that point to both confidence in the equity story and caution around execution risk.Narrative Update • Mar 21
SOBI: Kidney And Sepsis Progress Will Support A More Constructive Outlook
Analyst price targets for Swedish Orphan Biovitrum have moved higher toward SEK 470 to SEK 500, as analysts highlight their updated views following recent rating changes and an upgraded stance from several firms. Analyst Commentary Recent research updates on Swedish Orphan Biovitrum show a mix of optimism around upside potential and some caution on how much of that is already reflected in the share price.Narrative Update • Mar 07
SOBI: Kidney And Sepsis Advances Will Support A More Upbeat Outlook
The analyst fair value estimate for Swedish Orphan Biovitrum has been adjusted from SEK 416 to SEK 424, reflecting recent price target increases to SEK 470 and SEK 500, as well as updated analyst views on revenue growth, margins and future P/E assumptions. Analyst Commentary Recent Street research on Swedish Orphan Biovitrum presents a mix of optimism and caution around the shares, which helps frame the updated fair value estimate of SEK 424.
New Narrative • Feb 24
Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare disease medicines across hematology, immunology and specialty care. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 20
SOBI: Kidney And Sepsis Progress And Mixed Ratings Will Support Balanced Outlook
Narrative update The analyst price target for Swedish Orphan Biovitrum has been revised from about SEK 375.64 to SEK 416.45, with analysts citing updated assumptions on revenue growth, profit margins and future P/E, together with mixed recent rating changes, as the main drivers of this change. Analyst Commentary Recent rating changes show that analysts are split on Swedish Orphan Biovitrum, with one upgrade and one downgrade in quick succession.
New Narrative • Feb 08
Launch Wave In Rare Disease Treatments Will Redefine Long Term Potential
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare diseases in hematology, immunology and specialty care, with a growing portfolio of high-value medicines. What are the underlying business or industry changes driving this perspective?Analysis Article • Feb 08
Swedish Orphan Biovitrum AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ) shareholders, with its shares surging...Narrative Update • Feb 06
SOBI: Kidney And Sepsis Pipeline Progress Will Support Fairly Valued Outlook
Analysts have nudged their price target on Swedish Orphan Biovitrum slightly higher to around SEK 376 from roughly SEK 372, reflecting updated assumptions that combine a modestly adjusted discount rate and revenue growth outlook with expectations for stronger profit margins and a somewhat lower future P/E multiple. What's in the News European Commission approves Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 years with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, to be used with a renin angiotensin system inhibitor where tolerated, following a positive CHMP opinion in December 2025 (Key Developments).Narrative Update • Jan 22
SOBI: Upgraded Buy Rating And Pipeline Progress Are Expected To Drive Returns
Analysts have nudged their price target for Swedish Orphan Biovitrum slightly higher to SEK 372.42 from SEK 371.18. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E after recent research including an upgrade to Buy.Narrative Update • Jan 08
SOBI: Pipeline Milestones And Buy Rating Are Expected To Shape Returns
Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 367.09 to about SEK 371.18, reflecting updated assumptions around discount rate, profit margin and a slightly higher future P/E, along with recent research that included an upgrade to Buy with a SEK 370 target. Analyst Commentary Bullish Takeaways Bullish analysts point to the SEK 370 price target as support for the view that the revised assumptions on discount rate, profit margin and future P/E still leave room for upside versus the previous framework.Analysis Article • Jan 05
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Dec 17
SOBI: Rare Disease Pipeline Progress Will Drive Future Share Price Upside
Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 360 to SEK 367, reflecting slightly improved fair value assumptions and confidence in the company’s future earnings backed by recent positive research commentary. Analyst Commentary Recent upgrades reflect a growing conviction that Swedish Orphan Biovitrum can deliver attractive risk adjusted returns at current levels, with the new SEK 370 price target signaling modest upside from the revised fair value range.Narrative Update • Dec 03
SOBI: Rare Disease Portfolio And Regulatory Milestones Will Shape Future Performance
Analysts have modestly raised their price target on Swedish Orphan Biovitrum to SEK 370 from about SEK 360, reflecting slightly higher confidence in the company’s long term earnings profile and valuation multiple. Analyst Commentary Analysts note that the recent move to a Buy rating and SEK 370 price target reflects increasing conviction that Swedish Orphan Biovitrum can sustain attractive revenue growth while expanding margins, supporting a higher valuation multiple compared to historical levels.Analysis Article • Dec 01
Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S
Swedish Orphan Biovitrum AB (publ)'s ( STO:SOBI ) price-to-sales (or "P/S") ratio of 4.2x might make it look like a buy...Narrative Update • Nov 19
SOBI: Regulatory Approvals And Revised Guidance Will Shape Performance Amid Competition
Narrative Update on Swedish Orphan Biovitrum Analysts have raised their price target for Swedish Orphan Biovitrum from SEK 351.09 to SEK 360.36, citing improved growth forecasts and stronger profit margin expectations. Analyst Commentary Bullish Takeaways Bullish analysts believe that robust revenue growth prospects support a higher valuation for Swedish Orphan Biovitrum.Narrative Update • Nov 04
SOBI: Upgraded Recommendation Signals Confidence Amid Balanced Risks And Advancing Pipeline
Narrative Update on Swedish Orphan Biovitrum Analysts have raised their price target for Swedish Orphan Biovitrum from SEK 336 to SEK 351.09, citing improved revenue growth expectations and recent positive research sentiment. Analyst Commentary Recent research updates reflect shifting sentiment toward Swedish Orphan Biovitrum, with analysts adjusting forecasts and recommendations based on the company's financial performance and growth outlook.Analysis Article • Oct 28
Swedish Orphan Biovitrum's (STO:SOBI) Soft Earnings Are Actually Better Than They Appear
Shareholders appeared unconcerned with Swedish Orphan Biovitrum AB (publ)'s ( STO:SOBI ) lackluster earnings report...Narrative Update • Oct 21
Analysts Trim Sobi Price Target as Outlook Improves and Product Pipeline Advances
Analysts have slightly lowered their price target for Swedish Orphan Biovitrum from SEK 340.27 to SEK 336.00. They cite a modest reduction in projected revenue growth and profit margins, as well as a minor uptick in discount rates.Analysis Article • Oct 19
Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Sep 24
Altuvoct Adoption And Gamifant Launches Will Unlock European Opportunities
Both the Discount Rate and Net Profit Margin for Swedish Orphan Biovitrum remained essentially stable, supporting the analyst consensus price target, which saw only a marginal decrease from SEK341.18 to SEK340.27. What's in the News Tryngolza (olezarsen) approved in the EU as adjunct therapy for adults with genetically confirmed familial chylomicronemia syndrome (FCS), based on positive Phase 3 data; Sobi holds exclusive commercialization rights outside the U.S., Canada, and China.Analysis Article • Aug 04
We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jul 19
Results: Swedish Orphan Biovitrum AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ) shareholders are probably feeling a little disappointed, since its...Analysis Article • Jul 03
Are Investors Undervaluing Swedish Orphan Biovitrum AB (publ) (STO:SOBI) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Swedish Orphan Biovitrum fair value estimate is kr562 Swedish...
New Narrative • Nov 20
Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio
Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.Shareholder Returns
| SOBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.0% | -0.8% | 0.03% |
| 1Y | 45.4% | 21.1% | 11.2% |
Return vs Industry: SOBI exceeded the Swedish Biotechs industry which returned 21.1% over the past year.
Return vs Market: SOBI exceeded the Swedish Market which returned 11.2% over the past year.
Price Volatility
| SOBI volatility | |
|---|---|
| SOBI Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 14.0% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: SOBI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SOBI's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,969 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBI fundamental statistics | |
|---|---|
| Market cap | SEK 154.04b |
| Earnings (TTM) | SEK 921.00m |
| Revenue (TTM) | SEK 28.96b |
167.7x
P/E Ratio5.3x
P/S RatioIs SOBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBI income statement (TTM) | |
|---|---|
| Revenue | SEK 28.96b |
| Cost of Revenue | SEK 6.17b |
| Gross Profit | SEK 22.78b |
| Other Expenses | SEK 21.86b |
| Earnings | SEK 921.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 16, 2026
| Earnings per share (EPS) | 2.66 |
| Gross Margin | 78.68% |
| Net Profit Margin | 3.18% |
| Debt/Equity Ratio | 46.3% |
How did SOBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 17:55 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 28 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Xue Chen | Barclays |
| Rosie Turner | Barclays |